Feb 24, 2025
Jeffrey Meckler, CEO of Indaptus Therapeutics, is focused on using their decoy platform to activate the immune system to fight cancer and infections. This approach activates the innate and adaptive pathways in a controlled manner using a short-term pulsed dosing regimen and helps avoid the toxicity issues seen in...
Feb 24, 2025
Jeffrey Meckler, CEO of Indaptus Therapeutics, is focused on using their decoy platform to activate the immune system to fight cancer and infections. This approach activates the innate and adaptive pathways in a controlled manner using a short-term pulsed dosing regimen and helps avoid the toxicity issues seen in...
May 23, 2024
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPα...
May 23, 2024
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPα...
Nov 21, 2023
Dr. Juan Vera, CEO of Marker Therapeutics, a clinical-stage immuno-oncology company, is developing next-generation immunotherapy with a multi-tumor-specific T-cell platform to overcome limitations of current T-cell therapies with narrow target recognition. This approach, which recognizes multiple antigens within the...